Clinical trials: Clear Cell Tumor
Ewing Sarcoma, Myxoid Liposarcoma
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing sarcoma; AND dose expansion of the combination…
- Conditions
- Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor
- Trial name
- NCT03600649
- Testing
- Seclidemstat, Cyclophosphamide, Topotecan
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Salarius Pharmaceuticals, LLC
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell…
- Trial name
- NCT05239728
- Testing
- Belzutifan, Pembrolizumab
- Where
- 285 sites in United States, Australia and 30 more
- Volunteers
- 1,800 people
- Sponsor
- Merck Sharp & Dohme LLC
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
This randomized pilot clinical trial studies the side effects of tremelimumab with or without tissue cryoablation in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT02626130
- Testing
- Cryosurgery, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Neoplasms, Targeted Molecular Therapy
A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Whether patients with stage III clear cell renal cell carcinoma(ccRCC) should receive adjuvant targeted therapy or not is still on debate.
- Trial name
- NCT02688491
- Testing
- sunitinib
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Advanced Cancer, Clear Cell Renal Cell Carcinoma
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT05663710
- Testing
- 177Lu girentuximab, Nivolumab, Cabozantinib
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
This randomized phase II trial studies different combinations of bevacizumab, temsirolimus, and sorafenib tosylate to see how well they work compared with bevacizumab alone in treating patients with kidney cancer that has spread…
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT00378703
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 559 sites in United States, Peru
- Volunteers
- 361 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01307631
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Clear Cell Metastatic Renal Cell Carcinoma
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
Disease and Stage: naïve metastatic kidney cancer. A multicenter, randomized, a Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer
- Trial name
- BIONIKK (NCT02960906)
- Testing
- Nivolumab, Ipilimumab, Pazopanib
- Where
- 16 sites in France
- Volunteers
- 200 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Endometrioid Carcinoma, Clear Cell Carcinoma
Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)
The purpose of this study is to determine whether a relationship exists between a previously established diagnosis of endometriosis and the consecutive risk of developing a clear cell or endometrioid ovarian carcinoma.
- Conditions
- Endometrioid Carcinoma, Clear Cell Carcinoma, Endometriosis
- Trial name
- EAOC (NCT01732432)
- Sponsor
- University Hospital, Basel, Switzerland
Advanced Solid Tumors, Solid Tumor
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
- Conditions
- Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult
- Trial name
- NCT02974738
- Testing
- Belzutifan
- Volunteers
- 120 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Carcinoma, Renal Cell
Sunitinib in Metastatic Renal Cancer
Sunitinib is the registered treatment for first-line therapy of metastatic clear-cell carcinoma of the kidney.Data from the Expanded Access Study have shown activity also in non-clear cell renal cancer (NCCRC).
- Trial name
- NCT01034878
- Testing
- Sunitinib
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Istituto Clinico Humanitas
Advanced Clear Cell Renal Cell Carcinoma
A Clinical Study of 6MW3211 in Patients With Renal Cancer
single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer
- Trial name
- NCT05440045
- Testing
- 6MW3211
- Volunteers
- 30 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00066651
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Bellini Carcinoma, Collecting Duct Carcinoma
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
This is a single-arm, monocentric, phase II trial, enrolling patients with histological diagnosis of collecting duct carcinoma and renal medullary carcinoma with locally advanced or metastatic disease who will be treated with…
- Conditions
- Bellini Carcinoma, Collecting Duct Carcinoma, Renal Medullary Carcinoma
- Trial name
- REPRINT (NCT06302569)
- Testing
- Pembrolizumab + Enfortumab Vedotin
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Giuseppe Procopio
Clear Cell Renal Cell Carcinoma and Glioblastoma
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and…
- Trial name
- NCT07067905
- Testing
- 68Ga-XT771
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chinese PLA General Hospital
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma
- Trial name
- NCT00888173
- Testing
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Where
- 35 sites in United States
- Volunteers
- 45 people
- Sponsor
- Gynecologic Oncology Group
Metastatic Renal Cell Carcinoma
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab…
- Trial name
- NCT03075423
- Testing
- Ipilimumab plus nivolumab, Standard Therapy
- Where
- 30 sites in Belgium, Czechia and 5 more
- Volunteers
- 316 people
- Sponsor
- Goethe University
Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian…
- Conditions
- Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma
- Trial name
- FRAPPE (NCT05920798)
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic